Advanced search
Publication Cover
Immunological Investigations
A Journal of Molecular and Cellular Immunology
Volume 45, 2016 - Issue 8: Contribution of Tregs in Disease
Submit an article Journal homepage
650
Views
19
CrossRef citations to date
0
Altmetric
Review Articles

Co-stimulate or Co-inhibit Regulatory T Cells, Which Side to Go?

Weifeng LiuDepartment of Biochemistry, Albert Einstein College of Medicine, Bronx, NY, USA;Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY, USAView further author information
,
Steven C. AlmoDepartment of Biochemistry, Albert Einstein College of Medicine, Bronx, NY, USAView further author information
&
Xingxing ZangDepartment of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY, USA;Department of Medicine, Albert Einstein College of Medicine, Bronx, NY, USA;Department of Urology, Albert Einstein College of Medicine, Bronx, NY, USACorrespondence[email protected]
View further author information
Pages 813-831 | Published online: 15 Jul 2016

References

  • Abadi YM, Jeon H, Ohaegbulam KC, et al. (2013). Host b7x promotes pulmonary metastasis of breast cancer. J Immunol, 190, 3806–14.
  • Acuto O, Michel F. (2003). CD28-mediated co-stimulation: A quantitative support for TCR signalling. Nat Rev Immunol, 3, 939–51.
  • Amarnath S, Mangus CW, Wang JC, et al. (2011). The PDL1-PD1 axis converts human TH1 cells into regulatory T cells. Sci Transl Med, 3, 111ra120–111ra120.
  • Asano M, Toda M, Sakaguchi N, Sakaguchi S. (1996). Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation. J Exp Med, 184, 387–96.
  • Assal A, Kaner J, Pendurti G, Zang X. (2015). Emerging targets in cancer immunotherapy: Beyond CTLA-4 and PD-1. Immunotherapy, 7, 1169–86.
  • Belkaid Y, Rouse BT. (2005). Natural regulatory T cells in infectious disease. Nat Immunol, 6, 353–60.
  • Bennett CL, Christie J, Ramsdell F, Brunkow ME, et al. (2001). The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet, 27, 20–21.
  • Beyersdorf N, Gaupp S, Balbach K, et al. (2005). Selective targeting of regulatory T cells with CD28 superagonists allows effective therapy of experimental autoimmune encephalomyelitis. J Exp Med, 202, 445–55.
  • Bonomo A, Kehn PJ, Shevach EM. (1995). Post-thymectomy autoimmunity: Abnormal T-cell homeostasis. Immunol Today, 16, 61–7.
  • Bour‐Jordan H, Bluestone JA. (2009). Regulating the regulators: Costimulatory signals control the homeostasis and function of regulatory T cells. Immunol Rev, 229, 41–66.
  • Bulliard Y, Jolicoeur R, Windman M, et al. (2013). Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies. J Exp Med, 210, 1685–93.
  • Butte MJ, Keir ME, Phamduy TB, et al. (2007). Programmed death-1 ligand 1 interacts specifically with the B7–1 costimulatory molecule to inhibit T cell responses. Immunity, 27, 111–22.
  • Camisaschi C, Casati C, Rini F, et al. (2010). LAG-3 expression defines a subset of CD4+ CD25highFoxp3+ regulatory T cells that are expanded at tumor sites. J Immunol, 184, 6545–51.
  • Cederbom L, Hall H, Ivars F. (2000). CD4+ CD25+ regulatory T cells down‐regulate co‐stimulatory molecules on antigen‐presenting cells. Eur J Immunol, 30, 1538–43.
  • Chattopadhyay K, Lazar-Molnar E, Yan Q, et al. (2009). Sequence, structure, function, immunity: Structural genomics of costimulation. Immunol Rev, 229, 356–86.
  • Chattopadhyay K, Ramagopal UA, Brenowitz M, et al. (2008). Evolution of GITRL immune function: Murine GITRL exhibits unique structural and biochemical properties within the TNF superfamily. Proc Natl Acad Sci USA, 105, 635–40.
  • Chattopadhyay K, Ramagopal UA, Mukhopadhaya A, et al. (2007). Assembly and structural properties of glucocorticoid-induced TNF receptor ligand: Implications for function. Proc Natl Acad Sci USA, 104, 19452–7.
  • Chen L, Flies DB. (2013). Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol, 13, 227–42.
  • Chinai JM, Janakiram M, Chen F, et al. (2015). New immunotherapies targeting the PD-1 pathway. Trends Pharmacol Sci, 36, 587–95.
  • Chodon T, Koya RC, Odunsi K. (2015). Active immunotherapy of cancer. Immunol Invest, 44, 817–36.
  • Claus C, Riether C, Schürch C, et al. (2012). CD27 signaling increases the frequency of regulatory T cells and promotes tumor growth. Cancer Res, 72, 3664–76.
  • Collins AV, Brodie DW, Gilbert RJ, et al. (2002). The interaction properties of costimulatory molecules revisited. Immunity, 17, 201–10.
  • Compaan DM, Hymowitz SG. (2006). The crystal structure of the costimulatory OX40-OX40L complex. Structure, 14, 1321–30.
  • Conrad C, Gregorio J, Wang Y-H, et al. (2012). Plasmacytoid dendritic cells promote immunosuppression in ovarian cancer via ICOS costimulation of Foxp3+ T-regulatory cells. Cancer Res, 72, 5240–9.
  • Dai Z, Li Q, Wang Y, et al. (2004). CD4+ CD25+ regulatory T cells suppress allograft rejection mediated by memory CD8+ T cells via a CD30-dependent mechanism. J Clin Invest, 113, 310–7.
  • Elpek KG, Yolcu ES, Franke DD, et al. (2007). Ex vivo expansion of CD4+ CD25+ FoxP3+ T regulatory cells based on synergy between IL-2 and 4–1BB signaling. J Immunol, 179, 7295–304.
  • Ephrem A, Epstein AL, Stephens GL, et al. (2013). Modulation of Treg cells/T effector function by GITR signaling is context-dependent. Eur J Immunol, 43, 2421–9.
  • Faget J, Bendriss-Vermare N, Gobert M, et al. (2012). ICOS-ligand expression on plasmacytoid dendritic cells supports breast cancer progression by promoting the accumulation of immunosuppressive CD4+ T cells. Cancer Res, 72, 6130–41.
  • Fallarino F, Grohmann U, Hwang KW, et al. (2003). Modulation of tryptophan catabolism by regulatory T cells. Nat Immunol, 4, 1206–12.
  • Fisson S, Darrasse-Jèze G, Litvinova E, et al. (2003). Continuous activation of autoreactive CD4+ CD25+ regulatory T cells in the steady state. J Exp Med, 198, 737–46.
  • Fontenot JD, Gavin MA, Rudensky AY. (2003). Foxp3 programs the development and function of CD4+ CD25+ regulatory T cells. Nat Immunol, 4, 330–6.
  • Franceschini D, Paroli M, Francavilla V, et al. (2009). PD-L1 negatively regulates CD4+ CD25+ Foxp3+ Tregs by limiting STAT-5 phosphorylation in patients chronically infected with HCV. J Clin Invest, 119, 551–64.
  • Francisco LM, Sage PT, Sharpe AH. (2010). The PD‐1 pathway in tolerance and autoimmunity. Immunol Rev, 236, 219–42.
  • Francisco LM, Salinas VH, Brown KE, et al. (2009). PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med, 206, 3015–29.
  • Freeman GJ, Long AJ, Iwai Y, et al. (2000). Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med, 192, 1027–34.
  • Friedline RH, Brown DS, Nguyen H, et al. (2009). CD4+ regulatory T cells require CTLA-4 for the maintenance of systemic tolerance. J Exp Med, 206, 421–34.
  • Gett AV, Hodgkin PD. (2000). A cellular calculus for signal integration by T cells. Nat Immunol 1, 239–44.
  • Gimmi CD, Freeman GJ, Gribben JG, et al. (1991). B-cell surface antigen B7 provides a costimulatory signal that induces T cells to proliferate and secrete interleukin 2. Proc Natl Acad Sci U S A, 88, 6575–9.
  • Gogishvili T, Lühder F, Goebbels S, et al. (2013). Cell‐intrinsic and‐extrinsic control of Treg‐cell homeostasis and function revealed by induced CD28 deletion. Eur J Immunol, 43, 188–93.
  • Griseri T, Asquith M, Thompson C, Powrie F. (2010). OX40 is required for regulatory T cell–mediated control of colitis. J Exp Med, 207, 699–709.
  • Gupta S, Thornley TB, Gao W, Larocca R, et al. (2012). Allograft rejection is restrained by short-lived TIM-3+ PD-1+ Foxp3+ Tregs. J Clin Invest, 122, 2395–404.
  • Harding FA, McArthur JG, Gross JA, et al. (1992). CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature, 356, 607–9.
  • Haribhai D, Williams JB, Jia S, et al. (2011). A requisite role for induced regulatory T cells in tolerance based on expanding antigen receptor diversity. Immunity, 35, 109–22.
  • Hirschhorn-Cymerman D, Rizzuto GA, Merghoub T, et al. (2009). OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis. J Exp Med, 206, 1103–16.
  • Hodi FS, Butler M, Oble DA, et al. (2008). Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci U S A, 105, 3005–10.
  • Hori S, Haury M, Lafaille JJ, et al. (2002). Peripheral expansion of thymus‐derived regulatory cells in anti‐myelin basic protein T cell receptor transgenic mice. Eur J Immunol, 32, 3729–35.
  • Huang C-T, Workman CJ, Flies D, et al. (2004). Role of LAG-3 in regulatory T cells. Immunity, 21, 503–13.
  • Huang J, Jochems C, Talaie T, et al. (2012). Elevated serum soluble CD40 ligand in cancer patients may play an immunosuppressive role. Blood, 120, 3030–8.
  • Igarashi H, Cao Y, Iwai H, et al. (2008). GITR ligand-costimulation activates effector and regulatory functions of CD4+ T cells. Biochem Biophys Res Commun, 369, 1134–8.
  • Ise W, Kohyama M, Nutsch KM, et al. (2010). CTLA-4 suppresses the pathogenicity of self antigen-specific T cells by cell-intrinsic and cell-extrinsic mechanisms. Nat Immunol, 11, 129–35.
  • Ishida Y, Agata Y, Shibahara K, Honjo T. (1992). Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 11, 3887.
  • Jain N, Nguyen H, Chambers C, Kang J. (2010). Dual function of CTLA-4 in regulatory T cells and conventional T cells to prevent multiorgan autoimmunity. Proc Natl Acad Sci USA, 107, 1524–8.
  • Josefowicz SZ, Niec RE, Kim HY, et al. (2012). Extrathymically generated regulatory T cells control mucosal TH2 inflammation. Nature, 482, 395–9.
  • Kanamaru F, Youngnak P, Hashiguchi M, et al. (2004). Costimulation via glucocorticoid-induced TNF receptor in both conventional and CD25+ regulatory CD4+ T cells. J Immunol, 172, 7306–14.
  • Keir ME, Butte MJ, Freeman GJ, Sharpe AH. (2008). PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol, 26, 677–704.
  • Khattri R, Cox T, Yasayko S-A, Ramsdell F. (2003). An essential role for Scurfin in CD4+ CD25+ T regulatory cells. Nat Immunol, 4, 337–42.
  • Kim S-J, Ha G-H, Kim S-H, Kang C-D. (2014). Combination of cancer immunotherapy with clinically available drugs that can block immunosuppressive cells. Immunol Invest, 43, 517–34
  • Ko K, Yamazaki S, Nakamura K, et al. (2005). Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+ CD25+ CD4+ regulatory T cells. J Exp Med, 202, 885–91.
  • Koulova L, Clark EA, Shu G, Dupont B. (1991). The CD28 ligand B7/BB1 provides costimulatory signal for alloactivation of CD4+ T cells. J Exp Med, 173, 759–62.
  • Krupnick AS, Gelman AE, Barchet W, et al. (2005). Cutting edge: Murine vascular endothelium activates and induces the generation of allogeneic CD4+ 25+ Foxp3+ regulatory T cells. J Immunol, 175, 6265–70.
  • Kurtulus S, Sakuishi K, Ngiow S-F, et al. (2015). TIGIT predominantly regulates the immune response via regulatory T cells. J Clin Invest, 125, 4053–62.
  • Lenschow DJ, Herold KC, Rhee L, et al. (1996). CD28/B7 regulation of Th1 and Th2 subsets in the development of autoimmune diabetes. Immunity, 5, 285–93.
  • Lenschow DJ, Walunas TL, Bluestone JA. (1996). CD28/B7 system of T cell costimulation. Annu Rev Immunol, 14, 233–58.
  • Liakou CI, Kamat A, Tang DN, et al. (2008). CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc Natl Acad Sci USA. 105, 14987–92.
  • Liang B, Workman C, Lee J, et al. (2008). Regulatory T cells inhibit dendritic cells by lymphocyte activation gene-3 engagement of MHC class II. J Immunol, 180, 5916–26.
  • Lin CH, Hünig T. (2003). Efficient expansion of regulatory T cells in vitro and in vivo with a CD28 superagonist. Eur J Immunol, 33, 626–38.
  • Linsley PS, Brady W, Grosmaire L, et al. (1991). Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation. J Exp Med, 173, 721–30.
  • Malmström V, Shipton D, Singh B, et al. (2001). CD134L expression on dendritic cells in the mesenteric lymph nodes drives colitis in T cell-restored SCID mice. J Immunol, 166, 6972–81.
  • Martin-Orozco N, Li Y, Wang Y, et al. (2010). Melanoma cells express ICOS ligand to promote the activation and expansion of T-regulatory cells. Cancer Res, 70, 9581–90.
  • McHugh RS, Whitters MJ, Piccirillo CA, et al. (2002). CD4+ CD25+ immunoregulatory T cells: Gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity, 16, 311–23.
  • Meagher C, Tang Q, Fife BT, et al. (2008). Spontaneous development of a pancreatic exocrine disease in CD28-deficient NOD mice. J Immunol, 180, 7793–803.
  • Murata K, Nose M, Ndhlovu LC, et al. (2002). Constitutive OX40/OX40 ligand interaction induces autoimmune-like diseases. J Immunol, 169, 4628–36.
  • Ohaegbulam KC, Assal A, Lazar-Molnar E, et al. (2015). Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends Mol Med, 21, 24–33.
  • Okkenhaug K, Wu L, Garza KM, et al. (2001). A point mutation in CD28 distinguishes proliferative signals from survival signals. Nat Immunol, 2, 325–32.
  • Onishi Y, Fehervari Z, Yamaguchi T, Sakaguchi S. (2008). Foxp3+ natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation. Proc Natl Acad Sci USA, 105, 10113–8.
  • Pan P-Y, Ma G, Weber KJ, et al. (2010). Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer. Cancer Res, 70, 99–108.
  • Pandiyan P, Zheng L, Ishihara S, et al. (2007). CD4+ CD25+ Foxp3+ regulatory T cells induce cytokine deprivation–mediated apoptosis of effector CD4+ T cells. Nat Immunol, 8, 1353–62.
  • Park HJ, Park JS, Jeong YH, et al. (2015). PD-1 upregulated on regulatory T cells during chronic virus infection enhances the suppression of CD8+ T cell immune response via the interaction with PD-L1 expressed on CD8+ T cells. J Immunol 194, 5801–11.
  • Pasero C, Truneh A, Olive D. (2009). Cosignaling molecules around LIGHT-HVEM-BTLA: From immune activation to therapeutic targeting. Curr Mol Med, 9, 911–27.
  • Paterson AM, Lovitch SB, Sage PT, et al. (2015). Deletion of CTLA-4 on regulatory T cells during adulthood leads to resistance to autoimmunity. J Exp Med, 212, 1603–21.
  • Piconese S, Pittoni P, Burocchi A, et al. (2010). A non‐redundant role for OX40 in the competitive fitness of Treg in response to IL‐2. Eur J Immunol, 40, 2902–13.
  • Piconese S, Valzasina B, Colombo MP. (2008). OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection. J Exp Med, 205, 825–839.
  • Podojil JR, Liu LN, Marshall SA, et al. (2013). B7-H4Ig inhibits mouse and human T-cell function and treats EAE via IL-10/Treg-dependent mechanisms. J Autoimmun, 44, 71–81.
  • Ray A, Basu S, Williams CB, et al. (2012). A novel IL-10–independent regulatory role for B cells in suppressing autoimmunity by maintenance of regulatory T cells via GITR ligand. J Immunol, 188, 3188–98.
  • Read S, Greenwald R, Izcue A, et al. (2006). Blockade of CTLA-4 on CD4+ CD25+ regulatory T cells abrogates their function in vivo. J Immunol, 177, 4376–83.
  • Read S, Malmström V, Powrie F. (2000). Cytotoxic T lymphocyte–associated antigen 4 plays an essential role in the function of CD25+ CD4+ regulatory cells that control intestinal inflammation. J Exp Med, 192, 295–302.
  • Riella LV, Paterson AM, Sharpe AH, Chandraker A. (2012). Role of the PD‐1 Pathway in the Immune Response. Am J Transplant, 12, 2575–87.
  • Ronchetti S, Zollo O, Bruscoli S, et al. (2004). Frontline: GITR, a member of the TNF receptor superfamily, is costimulatory to mouse T lymphocyte subpopulations. Eur J Immunol, 34, 613–22.
  • Ruby CE, Yates MA, Hirschhorn-Cymerman D, et al. (2009). Cutting Edge: OX40 agonists can drive regulatory T cell expansion if the cytokine milieu is right. J Immunol, 183, 4853–7.
  • Rudd CE, Taylor A, Schneider H. (2009). CD28 and CTLA-4 coreceptor expression and signal transduction. Immunol Rev, 229, 12–26.
  • Sakaguchi S. (2005). Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol, 6, 345–52.
  • Sakaguchi S, Sakaguchi N, Asano M, et al. (1995). Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol, 155, 1151–64.
  • Sakaguchi S, Yamaguchi T, Nomura T, Ono M. (2008). Regulatory T cells and immune tolerance. Cell, 133, 775–87.
  • Sakuishi K, Ngiow SF, Sullivan JM, et al. (2013). TIM3+ FOXP3+ regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer. Oncoimmunology 2, e23849.
  • Salomon B, Bluestone JA. (2001). Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu. Rev. Immunol. 19, 225–252.
  • Salomon B, Lenschow DJ, Rhee L, et al. (2000). B7/CD28 costimulation is essential for the homeostasis of the CD4+ CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity 12, 431–440.
  • Samstein RM, Josefowicz SZ, Arvey A, et al. (2012). Extrathymic generation of regulatory T cells in placental mammals mitigates maternal-fetal conflict. Cell 150, 29–38.
  • Sansom DM, Walker LS. (2006). The role of CD28 and cytotoxic T‐lymphocyte antigen‐4 (CTLA‐4) in regulatory T‐cell biology. Immunol. Rev. 212, 131–148.
  • Schmidt EM, Wang CJ, Ryan GA, et al. (2009). Ctla-4 controls regulatory T cell peripheral homeostasis and is required for suppression of pancreatic islet autoimmunity. J Immunol, 182, 274–282.
  • Schoenbrunn A, Frentsch M, Kohler S, et al. (2012). A converse 4–1BB and CD40 ligand expression pattern delineates activated regulatory T cells (Treg) and conventional T cells enabling direct isolation of alloantigen-reactive natural Foxp3+ Treg. J Immunol, 189, 5985–94.
  • Schreiber TH, Podack ER. (2013). Immunobiology of TNFSF15 and TNFRSF25. Immunol Res, 57, 3–11.
  • Selby MJ, Engelhardt JJ, Quigley M, et al. (2013). Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol Res, 1, 32–42.
  • Sharma S, Rajasagi NK, Veiga-Parga T, Rouse BT. (2014). Herpes virus entry mediator (HVEM) modulates proliferation and activation of regulatory T cells following HSV-1 infection. Microb Infect, 16, 648–60.
  • Shevach EM, Stephens GL. (2006). The GITR–GITRL interaction: Co-stimulation or contrasuppression of regulatory activity? Nat Rev Immunol, 6, 613–8.
  • Shimizu J, Yamazaki S, Takahashi T, et al. (2002). Stimulation of CD25+ CD4+ regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol, 3, 135–42.
  • Simpson TR, Li F, Montalvo-Ortiz W, et al. (2013). Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma. J Exp Med, 210, 1695–710.
  • Singh B, Read S, Asseman C, et al. (2001). Control of intestinal inflammation by regulatory T cells. Immunol Rev, 182, 190–200.
  • So T, Croft M. (2007). Cutting edge: OX40 inhibits TGF-β-and antigen-driven conversion of naive CD4 T cells into CD25+ Foxp3+ T cells. J Immunol, 179, 1427–1430.
  • Sprent J. (2005). Swapping molecules during cell-cell interactions. Sci Signal, 2005, pe8–pe8.
  • Stephens GL, McHugh RS, Whitters MJ, et al. (2004). Engagement of glucocorticoid-induced TNFR family-related receptor on effector T cells by its ligand mediates resistance to suppression by CD4+CD25+ T cells. J Immunol, 173, 5008–20.
  • Stumpf M, Zhou X, Bluestone JA. (2013). The B7-independent isoform of CTLA-4 functions to regulate autoimmune diabetes. J Immunol, 190, 961–9.
  • Suntharalingam G, Perry MR, Ward S, et al. (2006). Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med, 355, 1018–28.
  • Tai X, Van Laethem F, Pobezinsky L, et al. (2012). Basis of CTLA-4 function in regulatory and conventional CD4+ T cells. Blood, 119, 5155–63.
  • Takahashi T, Tagami T, Yamazaki S, et al. (2000). Immunologic self-tolerance maintained by CD25+ CD4+ regulatory T cells constitutively expressing cytotoxic T lymphocyte–associated antigen 4. J Exp Med, 192, 303–10.
  • Takeda I, Ine S, Killeen N, et al. (2004). Distinct roles for the OX40-OX40 ligand interaction in regulatory and nonregulatory T cells. J Immunol, 172, 3580–9.
  • Tang AL, Teijaro JR, Njau MN, et al. (2008). CTLA4 expression is an indicator and regulator of steady-state CD4+ FoxP3+ T cell homeostasis. J Immunol, 181, 1806–13.
  • Tang Q, Adams JY, Tooley AJ, et al. (2006). Visualizing regulatory T cell control of autoimmune responses in nonobese diabetic mice. Nat Immunol, 7, 83–92.
  • Tang Q, Henriksen KJ, Bi M, et al. (2004). In vitro–expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J Exp Med, 199, 1455–65.
  • Tang Q, Henriksen KJ, Boden EK, et al. (2003). Cutting edge: CD28 controls peripheral homeostasis of CD4+ CD25+ regulatory T cells. J Immunol, 171, 3348–52.
  • Tang Q, Krummel MF. (2006). Imaging the function of regulatory T cells in vivo. Curr Opin Immunol, 18, 496–502.
  • Tao R, Wang L, Murphy KM, et al. (2008). Regulatory T cell expression of herpesvirus entry mediator suppresses the function of B and T lymphocyte attenuator-positive effector T cells. J Immunol, 180, 6649–55.
  • Teft WA, Kirchhof MG, Madrenas J. (2006). A molecular perspective of CTLA-4 function. Annu Rev Immunol 24, 65–97.
  • Thompson CB, Lindsten T, Ledbetter JA, et al. (1989). CD28 activation pathway regulates the production of multiple T-cell-derived lymphokines/cytokines. Proc Natl Acad Sci USA, 86, 1333–7.
  • Thornton AM, Piccirillo CA, Shevach EM. (2004). Activation requirements for the induction of CD4+ CD25+ T cell suppressor function. Eur J Immunol, 34, 366–76.
  • Tuyaerts S, Van Meirvenne S, Bonehill A, et al. (2007). Expression of human GITRL on myeloid dendritic cells enhances their immunostimulatory function but does not abrogate the suppressive effect of CD4+CD25+ regulatory T cells. J Leukoc Biol, 82, 93–105.
  • Valzasina B, Guiducci C, Dislich H, et al. (2005). Triggering of OX40 (CD134) on CD4+ CD25+ T cells blocks their inhibitory activity: A novel regulatory role for OX40 and its comparison with GITR. Blood, 105, 2845–51.
  • van Olffen RW, Koning N, van Gisbergen KP, (2009). GITR triggering induces expansion of both effector and regulatory CD4+ T cells in vivo. J Immunol, 182, 7490–500.
  • Verhagen J, Gabrysova L, Minaee S, et al. (2009). Enhanced selection of FoxP3+ T-regulatory cells protects CTLA-4-deficient mice from CNS autoimmune disease. Proc Natl Acad Sci USA, 106, 3306–11.
  • von Boehmer H. (2005). Mechanisms of suppression by suppressor T cells. Nat Immunol, 6, 338–44.
  • Vu MD, Xiao X, Gao W, et al. (2007). OX40 costimulation turns off Foxp3+ Tregs. Blood, 110, 2501–10.
  • Walker LS. (2013). Treg and CTLA-4: Two intertwining pathways to immune tolerance. J Autoimmun, 45, 49–57.
  • Walker LS, Chodos A, Eggena M, et al. (2003). Antigen-dependent proliferation of CD4+ CD25+ regulatory T cells in vivo. J Exp Med, 198, 249–58.
  • Wang C, Li Y, Proctor TM, Vandenbark AA, Offner H. (2010). Down‐modulation of programmed death 1 alters regulatory T cells and promotes experimental autoimmune encephalomyelitis. J Neurosci Res, 88, 7–15.
  • Wang L, Pino-Lagos K, de Vries VC, et al. (2008). Programmed death 1 ligand signaling regulates the generation of adaptive Foxp3+ CD4+ regulatory T cells. Proc Natl Acad Sci USA, 105, 9331–6.
  • Watts TH. (2005). TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol, 23, 23–68.
  • Wing K, Onishi Y, Prieto-Martin P, et al. (2008). CTLA-4 control over Foxp3+ regulatory T cell function. Science, 322, 271–5.
  • Wing K, Yamaguchi T, Sakaguchi S. (2011). Cell-autonomous and-non-autonomous roles of CTLA-4 in immune regulation. Trends Immunol, 32, 428–33.
  • Wollenberg I, Agua-Doce A, Hernández A, et al. (2011). Regulation of the germinal center reaction by Foxp3+ follicular regulatory T cells. J Immunol, 187, 4553–60.
  • Wu LX, La Rose J, Chen L, et al. (2005). CD28 regulates the translation of Bcl-xL via the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway. J Immunol, 174, 180–94.
  • Xiao Y, Yu S, Zhu B, et al. (2014). RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance. J Exp Med, 211, 943–59.
  • Yadav M, Stephan S, Bluestone JA. (2013). Peripherally induced tregs-role in immune homeostasis and autoimmunity. Front Immunol, 4, 3389.
  • Yi T, Li X, Yao S, et al. (2011). Host APCs augment in vivo expansion of donor natural regulatory T cells via B7H1/B7. 1 in allogeneic recipients. J Immunol, 186, 2739–49.
  • Zang X, Allison JP. (2007). The B7 family and cancer therapy: Costimulation and coinhibition. Clin Cancer Res, 13, 5271–9.
  • Zeiser R, Nguyen VH, Hou J-Z, et al. (2007). Early CD30 signaling is critical for adoptively transferred CD4+ CD25+ regulatory T cells in prevention of acute graft-versus-host disease. Blood, 109, 2225–33.
  • Zhang R, Borges CM, Fan MY, et al. (2015). Requirement for CD28 in effector regulatory T Cell Differentiation, CCR6 induction, and skin homing. J Immunol, 195, 4154–61.
  • Zhang R, Huynh A, Whitcher G, et al. (2013). An obligate cell-intrinsic function for CD28 in Tregs. J Clin Invest, 123, 580–93.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.